NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022 By: TheNewswire.com October 21, 2022 at 11:00 AM EDT NASDAQ: AGRX</a>), a women's healthcare company with FDA approval for their weekly women's birth control patch, Twirla®, and who is actively working on a growth strategy to increase their revenue for Q3 of 2022. Learn more about Agile Therapeutics in this interview video with CEO, Al Altomari! Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Visit 👉 https://agiletherapeutics.com/">Contact DetailsMatt Riley - Head of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.comCompany Websitehttps://agiletherapeutics.com/
NASDAQ: AGRX</a>), a women's healthcare company with FDA approval for their weekly women's birth control patch, Twirla®, and who is actively working on a growth strategy to increase their revenue for Q3 of 2022. Learn more about Agile Therapeutics in this interview video with CEO, Al Altomari! Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Visit 👉 https://agiletherapeutics.com/">Contact DetailsMatt Riley - Head of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.comCompany Websitehttps://agiletherapeutics.com/
